Developer docs
API playgroundTry for free, no card

Search company profiles

Intuitive Ventures

Full company profile

uuid00006av

Namestring
Intuitive Ventures
Legal namestring
Intuitive Surgical Operations, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Intuitive Ventures is the corporate venture capital arm of Intuitive Surgical Operations, Inc. (NASDAQ: ISRG), established in 2020 and headquartered in Sunnyvale, California. The fund focuses on early-stage healthcare startups developing next-horizon solutions across surgical robotics, medical devices, cell therapy, cardiovascular interventions, neuromodulation, AI-driven diagnostics, and digital health. With more than $250 million in assets under management and an active portfolio of 15+ companies, Intuitive Ventures provides equity capital — typically $5-10 million or more per first investment — alongside practical guidance drawn from Intuitive Surgical's three decades of healthcare, regulatory, and commercialization expertise.

The fund's product offering is differentiated less by novel technology than by embedded strategic support: portfolio companies gain access to Intuitive Surgical's clinical, technical, regulatory, and commercial network, and benefit from a partnership model that emphasizes rigor, decisiveness, and sustained engagement. Notable portfolio investments include Capstan Medical (robotic heart valve technology), Cellares (cell therapy manufacturing automation), VahatiCor (coronary microvascular dysfunction therapy), XII Medical (neuromodulation for sleep apnea), Amber Therapeutics (neuromodulation for urinary incontinence), Apreo Health (endobronchial emphysema treatment), Neocis (dental surgical robotics), Optellum (AI lung cancer diagnosis), Flywheel (imaging data platform), and Medcrypt (medical device cybersecurity), with named exits including KelaHealth and OrganOx.

Intuitive Ventures operates with a lean team of 1-10 employees led by Managing Partner and President Murielle Thinard McLane, with Executive Chairman Gary Guthart, PhD (also CEO of Intuitive Surgical), four venture advisors with clinical and operating backgrounds, and dedicated medical and finance professionals. As a wholly-owned subsidiary of a publicly traded strategic parent, the fund enjoys patient capital and access to a global commercialization infrastructure that most independent healthcare VCs cannot replicate, while operating with the agility of an independent venture fund.

Short descriptiontext

Intuitive Ventures is the corporate venture capital arm of Intuitive Surgical (NASDAQ: ISRG), investing $5-10M+ in early-stage healthcare startups across surgical robotics, medical devices, cell therapy, and digital health, with $250M+ AUM and 15+ portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital funding, healthcare investments, early-stage financing, medical technology investing, startup capital
Industry1 code
PRIMARYFSANAHAD
Corporate Accelerators & Startup Programs
NAICS code4 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles1 record
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Intuitive Ventures is the corporate venture capital fund of Intuitive Surgical Operations, Inc., deploying $5–10M+ average first investments into early-stage healthcare startups developing next-horizon medical technologies including surgical robotics, cell therapy, cardiovascular interventions, neuromodulation, and AI-driven diagnostics. Beyond capital, portfolio companies receive practical guidance drawn from Intuitive Surgical's deep technical, clinical, regulatory, and commercial experience spanning three decades.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Intuitive Ventures is a single unified corporate venture capital fund, not a product company. It operates as the venture arm of Intuitive Surgical, focusing on early-stage healthcare investments. The fund deploys capital across 15+ portfolio companies spanning medical devices, diagnostics, digital health, and healthcare technology. Beyond funding, the fund provides practical guidance, industry expertise, and network access to portfolio companies. The portfolio includes select investments in XII Medical (neuromodulation for sleep apnea), Amber Therapeutics (neuromodulation for urinary incontinence), Apreo Health (endobronchial treatment), Capstan Medical (robotic heart valve technology), Cellares (cell therapy manufacturing automation), Dragon Vascular (neurovascular solutions), Endogenex (GI/metabolic therapies), Flywheel (imaging data management), Medcrypt (medical device cybersecurity), Neocis (dental surgical robotics), Optellum (AI lung cancer diagnosis), Surge (immunotherapy delivery), and VahatiCor (cardiac microvascular dysfunction treatment), along with exited investments in KelaHealth and OrganOx.

Product and service1 record
1Intuitive Ventures Fund
CategoryVenture Capital Investment Fund
Description

Corporate venture capital fund providing $5–10M+ average first investments to early-stage healthcare startups, with $250M+ in assets under management. The fund invests across medical devices, surgical robotics, diagnostics, cell therapy, digital health, and related healthcare technology, and provides portfolio companies with practical guidance drawn from Intuitive Surgical's 30+ years of healthcare innovation experience.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Corporate venture capital arm of Medtronic, a global medical device leader. Directly comparable as a medical-device-focused CVC deploying strategic capital into early-stage companies, often providing clinical and regulatory expertise similar to Intuitive Ventures.

TypeDirect peer
Description

Corporate venture capital arm of Johnson & Johnson investing across medical devices, pharmaceuticals, and digital health. Comparable as a healthcare-focused CVC with multi-stage deployment and deep strategic resources available to portfolio companies.

TypeDirect peer
Description

Corporate venture capital arm of Roche investing in diagnostics, medical devices, and digital health. Comparable as a healthcare-focused CVC leveraging its parent's deep clinical and commercial expertise to support early-stage companies.

TypeDirect peer
Description

Corporate venture capital arm of Optum/UnitedHealth Group investing in healthcare technology, digital health, and AI-driven care. Comparable as a healthcare-focused CVC providing strategic capital with access to the parent's distribution and data assets.

TypeDirect peer
Description

Investment arm of the Novo Nordisk Foundation with significant healthcare and life sciences venture activity. Comparable as a long-horizon, healthcare-specialist investor with deep domain expertise and substantial AUM.

TypeDirect peer
Description

Healthcare and life-sciences-focused venture and growth fund within Bain Capital. Comparable as a multi-stage healthcare investor with multi-hundred-million-dollar fund sizes and concentrated exposure to medical devices and biotech.

TypeDirect peer
Description

Healthcare-dedicated investment firm across venture, growth, and credit strategies. Comparable as a deep healthcare-specialist investor with extensive portfolio breadth across devices, diagnostics, and digital health.

TypeDirect peer
Description

Healthcare and bio fund within Andreessen Horowitz, investing across digital health, biotech, and medical devices. Comparable as a multi-stage healthcare investor pairing capital with operator network value-add.

TypeBroad incumbent
Description

Broad technology and healthcare venture firm. Comparable as a healthcare-active generalist VC with deep portfolio exposure to medical devices, diagnostics, and digital health, though not a dedicated CVC.

108VC
TypeEmerging player
Description

Venture firm with meaningful healthcare and bio portfolio activity. Comparable as an active participant in healthcare venture rounds with a track record of building healthtech and medical device companies, though smaller and broader in mandate than Intuitive Ventures.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment21 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intuitive Ventures

Healthcare Venture Capitalventures.intuitive.com

Intuitive Ventures is the corporate venture capital arm of Intuitive Surgical (NASDAQ: ISRG), investing $5-10M+ in early-stage healthcare startups across surgical robotics, medical devices, cell therapy, and digital health, with $250M+ AUM and 15+ portfolio companies.

What Intuitive Ventures does

Intuitive Ventures is the corporate venture capital arm of Intuitive Surgical Operations, Inc. (NASDAQ: ISRG), established in 2020 and headquartered in Sunnyvale, California. The fund focuses on early-stage healthcare startups developing next-horizon solutions across surgical robotics, medical devices, cell therapy, cardiovascular interventions, neuromodulation, AI-driven diagnostics, and digital health. With more than $250 million in assets under management and an active portfolio of 15+ companies, Intuitive Ventures provides equity capital — typically $5-10 million or more per first investment — alongside practical guidance drawn from Intuitive Surgical's three decades of healthcare, regulatory, and commercialization expertise.

The fund's product offering is differentiated less by novel technology than by embedded strategic support: portfolio companies gain access to Intuitive Surgical's clinical, technical, regulatory, and commercial network, and benefit from a partnership model that emphasizes rigor, decisiveness, and sustained engagement. Notable portfolio investments include Capstan Medical (robotic heart valve technology), Cellares (cell therapy manufacturing automation), VahatiCor (coronary microvascular dysfunction therapy), XII Medical (neuromodulation for sleep apnea), Amber Therapeutics (neuromodulation for urinary incontinence), Apreo Health (endobronchial emphysema treatment), Neocis (dental surgical robotics), Optellum (AI lung cancer diagnosis), Flywheel (imaging data platform), and Medcrypt (medical device cybersecurity), with named exits including KelaHealth and OrganOx.

Intuitive Ventures operates with a lean team of 1-10 employees led by Managing Partner and President Murielle Thinard McLane, with Executive Chairman Gary Guthart, PhD (also CEO of Intuitive Surgical), four venture advisors with clinical and operating backgrounds, and dedicated medical and finance professionals. As a wholly-owned subsidiary of a publicly traded strategic parent, the fund enjoys patient capital and access to a global commercialization infrastructure that most independent healthcare VCs cannot replicate, while operating with the agility of an independent venture fund.

Intuitive Ventures firmographics

Firmographics
Name
Intuitive Ventures
Legal name
Intuitive Surgical Operations, Inc.
Website
https://ventures.intuitive.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Intuitive Ventures is the corporate venture capital arm of Intuitive Surgical (NASDAQ: ISRG), investing $5-10M+ in early-stage healthcare startups across surgical robotics, medical devices, cell therapy, and digital health, with $250M+ AUM and 15+ portfolio companies.
Ownership category
akta.pro rank

Intuitive Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAD
Corporate Accelerators & Startup Programs

Keywords

  • Venture capital funding
  • Healthcare investments
  • Early-stage financing
  • Medical technology investing
  • Startup capital

Where Intuitive Ventures is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Markets served

Intuitive Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels2 records

Intuitive Ventures product offering

Product offering

Core offering

Intuitive Ventures is the corporate venture capital fund of Intuitive Surgical Operations, Inc., deploying $5–10M+ average first investments into early-stage healthcare startups developing next-horizon medical technologies including surgical robotics, cell therapy, cardiovascular interventions, neuromodulation, and AI-driven diagnostics. Beyond capital, portfolio companies receive practical guidance drawn from Intuitive Surgical's deep technical, clinical, regulatory, and commercial experience spanning three decades.

Product overview

Intuitive Ventures is a single unified corporate venture capital fund, not a product company. It operates as the venture arm of Intuitive Surgical, focusing on early-stage healthcare investments. The fund deploys capital across 15+ portfolio companies spanning medical devices, diagnostics, digital health, and healthcare technology. Beyond funding, the fund provides practical guidance, industry expertise, and network access to portfolio companies. The portfolio includes select investments in XII Medical (neuromodulation for sleep apnea), Amber Therapeutics (neuromodulation for urinary incontinence), Apreo Health (endobronchial treatment), Capstan Medical (robotic heart valve technology), Cellares (cell therapy manufacturing automation), Dragon Vascular (neurovascular solutions), Endogenex (GI/metabolic therapies), Flywheel (imaging data management), Medcrypt (medical device cybersecurity), Neocis (dental surgical robotics), Optellum (AI lung cancer diagnosis), Surge (immunotherapy delivery), and VahatiCor (cardiac microvascular dysfunction treatment), along with exited investments in KelaHealth and OrganOx.

Differentiator

Problem solved

Functional benefit

Products and services

  • Intuitive Ventures Fund Corporate venture capital fund providing $5–10M+ average first investments to early-stage healthcare startups, with $250M+ in assets under management. The fund invests across medical devices, surgical robotics, diagnostics, cell therapy, digital health, and related healthcare technology, and provides portfolio companies with practical guidance drawn from Intuitive Surgical's 30+ years of healthcare innovation experience.

Companies that use Intuitive Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

Intuitive Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Intuitive Ventures partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Intuitive Ventures competitors and assessment

Company assessment

Direct peers

  • Medtronic Ventures: Corporate venture capital arm of Medtronic, a global medical device leader. Directly comparable as a medical-device-focused CVC deploying strategic capital into early-stage companies, often providing clinical and regulatory expertise similar to Intuitive Ventures.
  • Johnson & Johnson Innovation (JJDC): Corporate venture capital arm of Johnson & Johnson investing across medical devices, pharmaceuticals, and digital health. Comparable as a healthcare-focused CVC with multi-stage deployment and deep strategic resources available to portfolio companies.
  • Roche Venture Fund: Corporate venture capital arm of Roche investing in diagnostics, medical devices, and digital health. Comparable as a healthcare-focused CVC leveraging its parent's deep clinical and commercial expertise to support early-stage companies.
  • Optum Ventures: Corporate venture capital arm of Optum/UnitedHealth Group investing in healthcare technology, digital health, and AI-driven care. Comparable as a healthcare-focused CVC providing strategic capital with access to the parent's distribution and data assets.
  • Novo Holdings (Novo Ventures): Investment arm of the Novo Nordisk Foundation with significant healthcare and life sciences venture activity. Comparable as a long-horizon, healthcare-specialist investor with deep domain expertise and substantial AUM.
  • Bain Capital Life Sciences: Healthcare and life-sciences-focused venture and growth fund within Bain Capital. Comparable as a multi-stage healthcare investor with multi-hundred-million-dollar fund sizes and concentrated exposure to medical devices and biotech.
  • OrbiMed: Healthcare-dedicated investment firm across venture, growth, and credit strategies. Comparable as a deep healthcare-specialist investor with extensive portfolio breadth across devices, diagnostics, and digital health.
  • Andreessen Horowitz Bio: Healthcare and bio fund within Andreessen Horowitz, investing across digital health, biotech, and medical devices. Comparable as a multi-stage healthcare investor pairing capital with operator network value-add.

Broad incumbents

  • Khosla Ventures: Broad technology and healthcare venture firm. Comparable as a healthcare-active generalist VC with deep portfolio exposure to medical devices, diagnostics, and digital health, though not a dedicated CVC.

Emerging players

  • 8VC: Venture firm with meaningful healthcare and bio portfolio activity. Comparable as an active participant in healthcare venture rounds with a track record of building healthtech and medical device companies, though smaller and broader in mandate than Intuitive Ventures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights5 records

Customer concentration

Intuitive Ventures social profiles

Digital presence

Intuitive Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intuitive Ventures leadership team

Management profile

Number of profiles

Profiles13 records

Intuitive Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intuitive Ventures M&A and investment

M&A and investment

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intuitive Ventures

What does Intuitive Ventures do?

Intuitive Ventures is the corporate venture capital fund of Intuitive Surgical Operations, Inc., deploying $5–10M+ average first investments into early-stage healthcare startups developing next-horizon medical technologies including surgical robotics, cell therapy, cardiovascular interventions, neuromodulation, and AI-driven diagnostics. Beyond capital, portfolio companies receive practical guidance drawn from Intuitive Surgical's deep technical, clinical, regulatory, and commercial experience spanning three decades.

Is Intuitive Ventures a public or private company?

Intuitive Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Intuitive Ventures founded?

Intuitive Ventures was founded in 2020. It employs 1 to 10 people.

Where is Intuitive Ventures based?

Intuitive Ventures is headquartered in Sunnyvale, United States, in the North America region.

Who are Intuitive Ventures's main competitors?

Direct peers on record are Medtronic Ventures, Johnson & Johnson Innovation (JJDC), Roche Venture Fund, Optum Ventures, Novo Holdings (Novo Ventures), Bain Capital Life Sciences, OrbiMed and Andreessen Horowitz Bio. Khosla Ventures is listed as a broad incumbent. 8VC is listed as an emerging player.

Does Intuitive Ventures have an API?

No public API is recorded for Intuitive Ventures.

What industry is Intuitive Ventures in?

Intuitive Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAHAD, Corporate Accelerators & Startup Programs. Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AdvamedInvesting in Women’s Health Products and CompaniesAdvaMed is hosting the second webinar in its 2026 Women’s Health series, developed in partnership with the Medtech Investment Working Group, to explore investment strategies and market dynamics for women’s health products. The event features a panel of industry leaders from organizations such as Intuitive Ventures, Novocuff, and American Heart Association Ventures to discuss successes and challenges in the sector.Venture Capital Access OnlineCellares Grows Series D to $327 Million with $50 Million Prime Radiant Partners InvestmentPrime Radiant Partners invested $50 million in Cellares' Series D financing, bringing the total to $327 million. The investment supports Cellares' commercial-scale operations and IPO in 2027, as well as its European expansion in Leiden, Netherlands. The company also operates active programs with sponsors including Bristol Myers Squibb and Cabaletta Bio.Tech Funding NewsCathie Wood's ARK Invest joins Cellares' $277M round to help bring cell therapies to more patients — TFNARK Invest invested $20 million in Cellares' Series D, bringing the total round to $277 million. The funding will accelerate Cellares' global Smart Factory network ahead of commercial-scale manufacturing in 2027. Cellares has signed agreements with Cabaletta Bio and Bristol Myers Squibb.FinSMEsCellares Receives $20M Investment from ARK InvestCellares received a $20M investment from ARK Invest, bringing its Series D to $277M. The company, an IDMO, recently manufactured and delivered two GMP doses of rese-cel and signed a 10-year commercial supply agreement with Cabaletta Bio. It plans to scale cell therapy production for hundreds of thousands of patients annually starting in 2027.GlobeNewswireOrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo VenturesOrganOx completed its second private placement closing, raising $160 million in primary and secondary equity financing with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare. The company's metra platform has been used in over 5,000 liver transplants, and it is expanding into kidney transplants and a first-in-human study with eGenesis.GlobeNewswireOrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo VenturesOrganOx completed a second private placement closing with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare. The company raised $160 million in primary and secondary equity financing, bringing total funding to $160 million since February 2025. The funds will accelerate growth of its metra platform, used in over 5,000 liver transplants.MedTech DiveCapstan brings surgical robot to valve replacementCapstan Medical announced it has successfully completed its first human trial using a surgical robot to implant mitral valve replacement devices in two patients, marking a first in structural heart disease treatment. The startup has developed a compact valve and robotic delivery platform that addresses anatomical constraints which currently exclude over 80% of patients from existing investigational mitral valve replacement options. Capstan is backed by $110 million in funding including investment from Intuitive Ventures, and is working toward a pivotal trial with an FDA submission goal of bringing the valve system to market in 2028.Business Wire BlogScaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture AdvisorIntuitive Ventures appointed Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor to support its investment platform in minimally invasive care. The firm, with $250 million in assets under management, has backed 13 startups since 2020 and announced its $150 million Fund II in 2024.PR NewswireXII MEDICAL RAISES $45 MILLION IN SERIES B FINANCING TO ADVANCE BEST-IN-CLASS NEUROMODULATION THERAPY FOR OBSTRUCTIVE SLEEP APNEAXII Medical closed a $45 million Series B financing led by Omega Funds and Intuitive Ventures, with existing investors including Cleveland Clinic. The funds will support product and clinical development for its neuromodulation therapy for obstructive sleep apnea. The company plans to expand its team and collaborate with partners.DevicetalksHow do I get funding for a medical device? with Vivian Golfin, Intuitive VenturesVivian Golfin, a Senior Associate at Intuitive Ventures, discusses the role of venture capital in medical device development during an episode of MedtechWOMEN Talks. She emphasizes the importance of early engagement with investors and highlights key milestones such as first-in-human trials and pilot results for startups. The discussion also covers the evolving role of AI and ML in medical devices and the necessity of data diversity.